Personalized mRNA Vaccine Improves Melanoma Recurrence Outcomes

Detailed randomized Phase 3 results strengthen the case that individualized neoantigen vaccination can add to adjuvant PD-1 blockade in resected high-risk melanoma. The observed benefit is in recurrence and distant-metastasis endpoints; overall survival and…






